San Diego, Calif., February 24, 2003 - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will present at the Bio CEO & Investor Conference in New York at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) on Wednesday, February 26, 2003.
A live Web cast may be accessed via the Bio site at http://www.firstcallevents.com/service/ajwz375133567gf12.html, or by accessing Ligand's Web site at www.ligand.com, on the Investor Relations page under "Current Presentations."
About Ligand
Ligand discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
Contact:
Michael Watts
Director, Investor Relations and
Corporate Communications
(858) 550-7850
mwatts@ligand.com
